Advertisement
U.S. markets close in 3 hours 59 minutes
  • S&P 500

    5,254.23
    +5.74 (+0.11%)
     
  • Dow 30

    39,782.08
    +22.00 (+0.06%)
     
  • Nasdaq

    16,404.34
    +4.82 (+0.03%)
     
  • Russell 2000

    2,132.03
    +17.68 (+0.84%)
     
  • Crude Oil

    82.57
    +1.22 (+1.50%)
     
  • Gold

    2,233.90
    +21.20 (+0.96%)
     
  • Silver

    24.90
    +0.15 (+0.60%)
     
  • EUR/USD

    1.0803
    -0.0027 (-0.25%)
     
  • 10-Yr Bond

    4.1870
    -0.0090 (-0.21%)
     
  • GBP/USD

    1.2632
    -0.0006 (-0.05%)
     
  • USD/JPY

    151.3570
    +0.1110 (+0.07%)
     
  • Bitcoin USD

    71,288.26
    +2,386.86 (+3.46%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,964.97
    +32.99 (+0.42%)
     
  • Nikkei 225

    40,168.07
    -594.66 (-1.46%)
     

RedHill Biopharma Shares Jump After Data Publication From COVID-19 Study

  • RedHill Biopharma Ltd (NASDAQ: RDHL) announced the publication of positive data from a Phase 2 study RHB-107 (upamostat) in non-hospitalized symptomatic COVID-19 patients in the peer-reviewed International Journal of Infectious Diseases.

  • The study showed that RHB-107 met the primary endpoint of safety and tolerability and delivered promising efficacy results, despite the small number of patients in each treatment group, including faster recovery from severe COVID-19 symptoms and a 100% reduction in hospitalization due to COVID-19.

  • Related: RedHill Biopharma Says Its Oral Broad-Acting Antivirals Inhibit Dominant Omicron Sub-Variant BA.5.

  • Data showed a 100% reduction in hospitalization due to COVID-19, with zero patients (0/41) on the RHB-107 arms versus 15% (3/20) hospitalized on the placebo-controlled arm.

  • The study also showed an approximate 88% reduction in reported new severe COVID-19 symptoms after treatment initiation, with only 2.4% of the RHB-107 treated group (1/41) versus 20% (4/20) of patients in the placebo-controlled arm reporting new severe COVID-19 symptoms.

  • Further analysis showed faster recovery from severe COVID-19 symptoms with a median of 3 days to recovery with upamostat vs. eight days with placebo.

  • Price Action: RDHL shares are up 27.2% at $0.18 on the last check Tuesday.

See more from Benzinga

Don't miss real-time alerts on your stocks - join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Advertisement